Multivariate analysis for OS and LFS in 164 MDS patients who had cytogenetic data at diagnosis
| Variable . | OS . | LFS . | ||||||
|---|---|---|---|---|---|---|---|---|
| RR . | 95% CI . | P . | RR . | 95% CI . | P . | |||
| Lower . | Upper . | Lower . | Upper . | |||||
| Age* | 1.022 | 1.006 | 1.039 | .006† | 0.984 | 0.964 | 1.004 | .122 |
| Karyotype‡ | 0.590 | 0.251 | 1.387 | .226 | 0.454 | 0.118 | 1.740 | .249 |
| IPSS-R§ | 1.621 | 1.220 | 2.153 | .001† | 1.820 | 1.206 | 2.746 | .004† |
| ASXL1 | 1.039 | 0.491 | 2.201 | .920 | 4.065 | 1.576 | 10.483 | .004† |
| TP53 | 3.735 | 1.327 | 10.514 | .013† | 4.795 | 0.790 | 29.081 | .088 |
| EZH2 | 1.847 | 0.643 | 5.300 | .254 | 0.960 | 0.205 | 4.485 | .958 |
| SRSF2 | 0.985 | 0.448 | 2.168 | .971 | 0.678 | 0.214 | 2.151 | .510 |
| ZRSR2 | 1.068 | 0.502 | 2.272 | .863 | 0.442 | 0.121 | 1.614 | .216 |
| lncRNA score|| | 4.783 | 2.491 | 9.182 | <.001† | 7.670 | 2.702 | 21.772 | <.001† |
| Variable . | OS . | LFS . | ||||||
|---|---|---|---|---|---|---|---|---|
| RR . | 95% CI . | P . | RR . | 95% CI . | P . | |||
| Lower . | Upper . | Lower . | Upper . | |||||
| Age* | 1.022 | 1.006 | 1.039 | .006† | 0.984 | 0.964 | 1.004 | .122 |
| Karyotype‡ | 0.590 | 0.251 | 1.387 | .226 | 0.454 | 0.118 | 1.740 | .249 |
| IPSS-R§ | 1.621 | 1.220 | 2.153 | .001† | 1.820 | 1.206 | 2.746 | .004† |
| ASXL1 | 1.039 | 0.491 | 2.201 | .920 | 4.065 | 1.576 | 10.483 | .004† |
| TP53 | 3.735 | 1.327 | 10.514 | .013† | 4.795 | 0.790 | 29.081 | .088 |
| EZH2 | 1.847 | 0.643 | 5.300 | .254 | 0.960 | 0.205 | 4.485 | .958 |
| SRSF2 | 0.985 | 0.448 | 2.168 | .971 | 0.678 | 0.214 | 2.151 | .510 |
| ZRSR2 | 1.068 | 0.502 | 2.272 | .863 | 0.442 | 0.121 | 1.614 | .216 |
| lncRNA score|| | 4.783 | 2.491 | 9.182 | <.001† | 7.670 | 2.702 | 21.772 | <.001† |
Only variables with P ≤ .10 in univariate analysis were incorporated into the multivariate Cox proportional hazard regression analysis.
CI, confidence interval; LFS, leukemia-free survival; RR, relative risk.
Age as a continuous variable.
Statistically significant if P < .05.
Unfavorable cytogenetics vs others. Patients without chromosome data at diagnosis were not included in the analysis.
IPSS-R risk groups: very good, good, intermediate, poor, very poor.
High vs low lncRNA risk scores.